2026 Global: Anatomic Pathology Market-Competitive Review (2032) report
Description
The 2026 Global: Anatomic Pathology Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anatomic pathology market by geography and historical trend. The scope of the report extends to sizing of the anatomic pathology market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Danaher (including Leica Biosystems), Thermo Fisher Scientific, Roche (including Ventana), Agilent Technologies, Quest Diagnostics, Labcorp, Sakura Finetek, NeoGenomics, Cardinal Health, and Hologic are among the leading companies shaping the global anatomic pathology market due to their broad portfolios spanning instruments, reagents, consumables, digital pathology platforms, and laboratory services. Danaher’s Leica Biosystems is a market leader in tissue processing, microtomes, embedding, and histology automation and has continued to expand through strategic collaborations and localized manufacturing to support global pathology workflows. Thermo Fisher supplies a wide array of laboratory equipment and consumables essential to histopathology and molecular pathology workflows and leverages scale and integrated solutions that span specimen preparation to advanced diagnostics. Roche, through its Ventana subsidiary, offers automated IHC/ISH platforms and companion diagnostic assays that are central to precision oncology and pathology labs’ immunohistochemistry needs. Agilent Technologies provides pathology reagents, antibodies, and molecular diagnostic tools that support biomarker testing and research applications across anatomic pathology laboratories. Quest Diagnostics and Labcorp, as the two largest independent clinical laboratory providers, deliver high-volume anatomic pathology services, specialized oncology testing, and integrated molecular assays to health systems and clinicians while investing in precision oncology portfolios and biopharma services to support clinical trials and companion diagnostics.
Sakura Finetek, NeoGenomics, Cardinal Health, Hologic, and a group of specialized vendors complete the top-tier competitive landscape by focusing on niche technologies, reference services, and supply chain solutions that pathology laboratories depend upon. Sakura Finetek is recognized for tissue processors, embedding centers, and slide staining instruments that optimize histology throughput and quality. NeoGenomics has grown as a specialty oncology diagnostics and anatomic pathology services provider with particular strength in molecular profiling and targeted testing for cancer care. Cardinal Health supplies consumables, specimen-collection systems, and sundry pathology supplies at scale to laboratories and hospitals, playing a critical role in the supply chain continuity for daily pathology operations. Hologic (including its Biocare/analogs) contributes immunohistochemistry and cytology solutions that intersect anatomic pathology and women’s health diagnostics, supporting screening and diagnostic workflows. Beyond these ten, emerging digital pathology and AI companies (and LIS/LIMS vendors) increasingly partner with or are acquired by the major players to deliver end-to-end solutions that combine slide scanning, image analysis, and laboratory information systems integration.
Market dynamics favor companies that offer integrated consumables, automation, digital pathology platforms, and molecular diagnostics as demand for precision oncology, higher throughput, and telepathology rises; the consumables segment remains a major revenue driver while digital and AI-enabled platforms are accelerating transformation across service and instrument providers. Industry reports highlight sustained market growth driven by aging populations, rising cancer incidence, and adoption of advanced diagnostics—factors that reward scale, global distribution, and the ability to bundle instruments with recurring consumable and reagent revenue. Strategic moves such as collaborations, acquisitions, expansion of precision oncology test menus, and cloud-native digital pathology platforms are commonly cited as the primary methods these companies use to increase addressable market and deepen partnerships with health systems and biopharma customers.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anatomic pathology market by geography and historical trend. The scope of the report extends to sizing of the anatomic pathology market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Danaher (including Leica Biosystems), Thermo Fisher Scientific, Roche (including Ventana), Agilent Technologies, Quest Diagnostics, Labcorp, Sakura Finetek, NeoGenomics, Cardinal Health, and Hologic are among the leading companies shaping the global anatomic pathology market due to their broad portfolios spanning instruments, reagents, consumables, digital pathology platforms, and laboratory services. Danaher’s Leica Biosystems is a market leader in tissue processing, microtomes, embedding, and histology automation and has continued to expand through strategic collaborations and localized manufacturing to support global pathology workflows. Thermo Fisher supplies a wide array of laboratory equipment and consumables essential to histopathology and molecular pathology workflows and leverages scale and integrated solutions that span specimen preparation to advanced diagnostics. Roche, through its Ventana subsidiary, offers automated IHC/ISH platforms and companion diagnostic assays that are central to precision oncology and pathology labs’ immunohistochemistry needs. Agilent Technologies provides pathology reagents, antibodies, and molecular diagnostic tools that support biomarker testing and research applications across anatomic pathology laboratories. Quest Diagnostics and Labcorp, as the two largest independent clinical laboratory providers, deliver high-volume anatomic pathology services, specialized oncology testing, and integrated molecular assays to health systems and clinicians while investing in precision oncology portfolios and biopharma services to support clinical trials and companion diagnostics.
Sakura Finetek, NeoGenomics, Cardinal Health, Hologic, and a group of specialized vendors complete the top-tier competitive landscape by focusing on niche technologies, reference services, and supply chain solutions that pathology laboratories depend upon. Sakura Finetek is recognized for tissue processors, embedding centers, and slide staining instruments that optimize histology throughput and quality. NeoGenomics has grown as a specialty oncology diagnostics and anatomic pathology services provider with particular strength in molecular profiling and targeted testing for cancer care. Cardinal Health supplies consumables, specimen-collection systems, and sundry pathology supplies at scale to laboratories and hospitals, playing a critical role in the supply chain continuity for daily pathology operations. Hologic (including its Biocare/analogs) contributes immunohistochemistry and cytology solutions that intersect anatomic pathology and women’s health diagnostics, supporting screening and diagnostic workflows. Beyond these ten, emerging digital pathology and AI companies (and LIS/LIMS vendors) increasingly partner with or are acquired by the major players to deliver end-to-end solutions that combine slide scanning, image analysis, and laboratory information systems integration.
Market dynamics favor companies that offer integrated consumables, automation, digital pathology platforms, and molecular diagnostics as demand for precision oncology, higher throughput, and telepathology rises; the consumables segment remains a major revenue driver while digital and AI-enabled platforms are accelerating transformation across service and instrument providers. Industry reports highlight sustained market growth driven by aging populations, rising cancer incidence, and adoption of advanced diagnostics—factors that reward scale, global distribution, and the ability to bundle instruments with recurring consumable and reagent revenue. Strategic moves such as collaborations, acquisitions, expansion of precision oncology test menus, and cloud-native digital pathology platforms are commonly cited as the primary methods these companies use to increase addressable market and deepen partnerships with health systems and biopharma customers.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
